(RYAN) Ryan Specialty Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US78351F1075
Stock: Insurance, Underwriting, Distribution, Risk Management
Total Rating 16
Risk 65
Buy Signal -1.32
| Risk 5d forecast | |
|---|---|
| Volatility | 30.3% |
| Relative Tail Risk | -6.93% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.43 |
| Alpha | -47.33 |
| Character TTM | |
|---|---|
| Beta | -0.007 |
| Beta Downside | -0.285 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.53% |
| CAGR/Max DD | 0.07 |
EPS (Earnings per Share)
Revenue
Risks
Fundamental:
P/E ratio: 84.5106
Description: RYAN Ryan Specialty Holdings March 03, 2026
Ryan Specialty Group Holdings Inc. (NYSE: RYAN) is a Chicago-based wholesale broker and managing underwriter that delivers specialty insurance products and risk-management services across North America, Europe, and Asia-Pacific. Through delegated authority arrangements, it supports commercial, industrial, institutional, individual, and government clients by handling distribution, underwriting, product development, administration, and claims management.
As of the most recent quarter (Q4 2025), Ryan reported a 9% year-over-year increase in gross written premium to $2.58 billion and net income of $158 million, translating to earnings of $2.12 per share. The company’s market capitalization stands near $3.6 billion with a forward P/E of roughly 12.3, while its dividend yield remains around 2.0%. Industry-wide, rising demand for cyber-risk and climate-related specialty coverage, coupled with a modest rebound in investment-income yields after a period of low rates, are key drivers supporting Ryan’s growth trajectory.
For a deeper dive into Ryan’s valuation and how it fits within the broader insurance-broker landscape, you might explore the analysis on ValueRay.
Headlines to watch out for
- Wholesale brokerage commissions drive revenue growth
- Underwriting management fees impact profitability
- Insurance market cycles influence demand
- Regulatory changes affect operating costs
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 63.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.60 > 1.0 |
| NWC/Revenue: 18.39% < 20% (prev 9.53%; Δ 8.86% < -1%) |
| CFO/TA 0.06 > 3% & CFO 643.7m > Net Income 63.4m |
| Net Debt (3.53b) to EBITDA (805.4m): 4.38 < 3 |
| Current Ratio: 7.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (278.5m) vs 12m ago -4.40% < -2% |
| Gross Margin: 54.62% > 18% (prev 0.40%; Δ 5422 % > 0.5%) |
| Asset Turnover: 30.19% > 50% (prev 26.07%; Δ 4.12% > 0%) |
| Interest Coverage Ratio: 2.33 > 6 (EBITDA TTM 805.4m / Interest Expense TTM 222.4m) |
Altman Z'' 0.75
| A: 0.05 (Total Current Assets 647.3m - Total Current Liabilities 86.2m) / Total Assets 10.56b |
| B: 0.01 (Retained Earnings 120.4m / Total Assets 10.56b) |
| C: 0.05 (EBIT TTM 517.9m / Avg Total Assets 10.11b) |
| D: 0.01 (Book Value of Equity 134.5m / Total Liabilities 9.31b) |
| Altman-Z'' Score: 0.75 = B |
Beneish M -2.61
| DSRI: 1.03 (Receivables 489.0m/389.8m, Revenue 3.05b/2.52b) |
| GMI: 0.73 (GM 54.62% / 39.94%) |
| AQI: 1.90 (AQ_t 0.92 / AQ_t-1 0.48) |
| SGI: 1.21 (Revenue 3.05b / 2.52b) |
| TATA: -0.05 (NI 63.4m - CFO 643.7m) / TA 10.56b) |
| Beneish M-Score: -2.61 (Cap -4..+1) = A |
What is the price of RYAN shares?
As of March 09, 2026, the stock is trading at USD 39.72 with a total of 1,160,300 shares traded.
Over the past week, the price has changed by -1.22%, over one month by -8.97%, over three months by -26.01% and over the past year by -41.57%.
Over the past week, the price has changed by -1.22%, over one month by -8.97%, over three months by -26.01% and over the past year by -41.57%.
Is RYAN a buy, sell or hold?
Ryan Specialty Holdings has received a consensus analysts rating of 3.92.
Therefore, it is recommended to buy RYAN.
- StrongBuy: 4
- Buy: 5
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the RYAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.7 | 40.2% |
| Analysts Target Price | 55.7 | 40.2% |
RYAN Fundamental Data Overview March 08, 2026
P/E Trailing = 84.5106
P/E Forward = 16.7224
P/S = 3.5118
P/B = 7.872
Revenue TTM = 3.05b USD
EBIT TTM = 517.9m USD
EBITDA TTM = 805.4m USD
Long Term Debt = 3.29b USD (from longTermDebt, last quarter)
Short Term Debt = 112.2m USD (from shortTermDebt, last quarter)
Debt = 3.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.53b USD (from netDebt column, last quarter)
Enterprise Value = 14.04b USD (10.52b + Debt 3.68b - CCE 158.3m)
Interest Coverage Ratio = 2.33 (Ebit TTM 517.9m / Interest Expense TTM 222.4m)
EV/FCF = 24.39x (Enterprise Value 14.04b / FCF TTM 575.7m)
FCF Yield = 4.10% (FCF TTM 575.7m / Enterprise Value 14.04b)
FCF Margin = 18.87% (FCF TTM 575.7m / Revenue TTM 3.05b)
Net Margin = 2.08% (Net Income TTM 63.4m / Revenue TTM 3.05b)
Gross Margin = 54.62% ((Revenue TTM 3.05b - Cost of Revenue TTM 1.38b) / Revenue TTM)
Gross Margin QoQ = 90.21% (prev 47.57%)
Tobins Q-Ratio = 1.33 (Enterprise Value 14.04b / Total Assets 10.56b)
Interest Expense / Debt = 1.44% (Interest Expense 53.2m / Debt 3.68b)
Taxrate = 29.97% (13.4m / 44.6m)
NOPAT = 362.7m (EBIT 517.9m * (1 - 29.97%))
Current Ratio = 7.51 (Total Current Assets 647.3m / Total Current Liabilities 86.2m)
Debt / Equity = 5.68 (Debt 3.68b / totalStockholderEquity, last quarter 648.1m)
Debt / EBITDA = 4.38 (Net Debt 3.53b / EBITDA 805.4m)
Debt / FCF = 6.12 (Net Debt 3.53b / FCF TTM 575.7m)
Total Stockholder Equity = 607.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.63% (Net Income 63.4m / Total Assets 10.56b)
RoE = 10.43% (Net Income TTM 63.4m / Total Stockholder Equity 607.8m)
RoCE = 13.28% (EBIT 517.9m / Capital Employed (Equity 607.8m + L.T.Debt 3.29b))
RoIC = 8.88% (NOPAT 362.7m / Invested Capital 4.08b)
WACC = 4.62% (E(10.52b)/V(14.20b) * Re(5.89%) + D(3.68b)/V(14.20b) * Rd(1.44%) * (1-Tc(0.30)))
Discount Rate = 5.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 4.65%
[DCF] Terminal Value 88.06% ; FCFF base≈532.6m ; Y1≈630.3m ; Y5≈975.9m
[DCF] Fair Price = 192.9 (EV 28.54b - Net Debt 3.53b = Equity 25.01b / Shares 129.7m; r=5.90% [WACC]; 5y FCF grow 19.57% → 2.90% )
EPS Correlation: 73.41 | EPS CAGR: 18.25% | SUE: -4.0 | # QB: 0
Revenue Correlation: 93.01 | Revenue CAGR: 19.36% | SUE: -2.69 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.76 | Chg7d=-0.002 | Chg30d=-0.013 | Revisions Net=-11 | Analysts=17
EPS current Year (2026-12-31): EPS=2.29 | Chg7d=+0.005 | Chg30d=-0.093 | Revisions Net=-15 | Growth EPS=+17.0% | Growth Revenue=+13.3%
EPS next Year (2027-12-31): EPS=2.68 | Chg7d=-0.007 | Chg30d=-0.158 | Revisions Net=-11 | Growth EPS=+17.0% | Growth Revenue=+13.5%
[Analyst] Revisions Ratio: -0.85 (1 Up / 12 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.8% (Discount Rate 7.9% - Earnings Yield 1.2%)
[Growth] Growth Spread = +6.1% (Analyst 12.9% - Implied 6.8%)
P/E Forward = 16.7224
P/S = 3.5118
P/B = 7.872
Revenue TTM = 3.05b USD
EBIT TTM = 517.9m USD
EBITDA TTM = 805.4m USD
Long Term Debt = 3.29b USD (from longTermDebt, last quarter)
Short Term Debt = 112.2m USD (from shortTermDebt, last quarter)
Debt = 3.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.53b USD (from netDebt column, last quarter)
Enterprise Value = 14.04b USD (10.52b + Debt 3.68b - CCE 158.3m)
Interest Coverage Ratio = 2.33 (Ebit TTM 517.9m / Interest Expense TTM 222.4m)
EV/FCF = 24.39x (Enterprise Value 14.04b / FCF TTM 575.7m)
FCF Yield = 4.10% (FCF TTM 575.7m / Enterprise Value 14.04b)
FCF Margin = 18.87% (FCF TTM 575.7m / Revenue TTM 3.05b)
Net Margin = 2.08% (Net Income TTM 63.4m / Revenue TTM 3.05b)
Gross Margin = 54.62% ((Revenue TTM 3.05b - Cost of Revenue TTM 1.38b) / Revenue TTM)
Gross Margin QoQ = 90.21% (prev 47.57%)
Tobins Q-Ratio = 1.33 (Enterprise Value 14.04b / Total Assets 10.56b)
Interest Expense / Debt = 1.44% (Interest Expense 53.2m / Debt 3.68b)
Taxrate = 29.97% (13.4m / 44.6m)
NOPAT = 362.7m (EBIT 517.9m * (1 - 29.97%))
Current Ratio = 7.51 (Total Current Assets 647.3m / Total Current Liabilities 86.2m)
Debt / Equity = 5.68 (Debt 3.68b / totalStockholderEquity, last quarter 648.1m)
Debt / EBITDA = 4.38 (Net Debt 3.53b / EBITDA 805.4m)
Debt / FCF = 6.12 (Net Debt 3.53b / FCF TTM 575.7m)
Total Stockholder Equity = 607.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.63% (Net Income 63.4m / Total Assets 10.56b)
RoE = 10.43% (Net Income TTM 63.4m / Total Stockholder Equity 607.8m)
RoCE = 13.28% (EBIT 517.9m / Capital Employed (Equity 607.8m + L.T.Debt 3.29b))
RoIC = 8.88% (NOPAT 362.7m / Invested Capital 4.08b)
WACC = 4.62% (E(10.52b)/V(14.20b) * Re(5.89%) + D(3.68b)/V(14.20b) * Rd(1.44%) * (1-Tc(0.30)))
Discount Rate = 5.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 4.65%
[DCF] Terminal Value 88.06% ; FCFF base≈532.6m ; Y1≈630.3m ; Y5≈975.9m
[DCF] Fair Price = 192.9 (EV 28.54b - Net Debt 3.53b = Equity 25.01b / Shares 129.7m; r=5.90% [WACC]; 5y FCF grow 19.57% → 2.90% )
EPS Correlation: 73.41 | EPS CAGR: 18.25% | SUE: -4.0 | # QB: 0
Revenue Correlation: 93.01 | Revenue CAGR: 19.36% | SUE: -2.69 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.76 | Chg7d=-0.002 | Chg30d=-0.013 | Revisions Net=-11 | Analysts=17
EPS current Year (2026-12-31): EPS=2.29 | Chg7d=+0.005 | Chg30d=-0.093 | Revisions Net=-15 | Growth EPS=+17.0% | Growth Revenue=+13.3%
EPS next Year (2027-12-31): EPS=2.68 | Chg7d=-0.007 | Chg30d=-0.158 | Revisions Net=-11 | Growth EPS=+17.0% | Growth Revenue=+13.5%
[Analyst] Revisions Ratio: -0.85 (1 Up / 12 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.8% (Discount Rate 7.9% - Earnings Yield 1.2%)
[Growth] Growth Spread = +6.1% (Analyst 12.9% - Implied 6.8%)